Wellington Management Group Portfolio holdings
Wellington Management Group, founded in 1928 by Walter L. Morgan and headquartered in Boston, Massachusetts, is one of the world’s largest independent asset management firms, overseeing trillions in assets for a diverse client base including pension funds, endowments, and mutual fund investors. Renowned for its active management approach, Wellington offers a broad range of investment strategies across equities, fixed income, multi-asset, and alternative investments, emphasizing deep research and long-term partnerships with clients. The firm gained early fame for launching the Wellington Fund, one of the first balanced mutual funds, and has since maintained a reputation for disciplined, collaborative portfolio management. With a global presence and a focus on customized solutions, Wellington remains a trusted name in institutional and retail investing.
Top Buys
| 1 |
Apple
AAPL
|
$9.29B |
| 2 |
NVIDIA
NVDA
|
$1.77B |
| 3 |
Broadcom
AVGO
|
$1.59B |
| 4 |
SPDR S&P 500 ETF Trust
SPY
|
$1.52B |
| 5 |
T-Mobile US
TMUS
|
$1.48B |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
$3.16B |
| 2 |
Alphabet (Google) Class A
GOOGL
|
$2.92B |
| 3 |
Amazon
AMZN
|
$2.22B |
| 4 |
Microsoft
MSFT
|
$2.14B |
| 5 |
Merck
MRK
|
$1.72B |
Sector Composition
| 1 | Technology | 24.16% |
| 2 | Healthcare | 19.43% |
| 3 | Financials | 13.51% |
| 4 | Consumer Discretionary | 9.13% |
| 5 | Industrials | 9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1576
Annexon
ANNX
$238M
| $948K | ﹤0.01% |
193,419
+23,849
| +14% | +$117K |
|
1577
Iovance Biotherapeutics
IOVA
$901M
| $942K | ﹤0.01% |
117,418
+7,199
| +7% | +$57.7K |
|
1578
EyePoint Pharmaceuticals
EYPT
$966M
| $937K | ﹤0.01% |
+107,756
| New | +$937K |
|
1579
Avnet
AVT
$4.49B
| $934K | ﹤0.01% |
+18,139
| New | +$934K |
|
1580
Humacyte
HUMA
$226M
| $933K | ﹤0.01% |
194,324
-3,740
| -2% | -$18K |
|
|
TSVT
1581
DELISTED
2seventy bio
TSVT
| $925K | ﹤0.01% |
240,367
+38,294
| +19% | +$147K |
|
1582
Xencor
XNCR
$610M
| $925K | ﹤0.01% |
48,870
+6,554
| +15% | +$124K |
|
1583
Kura Oncology
KURA
$713M
| $923K | ﹤0.01% |
44,849
+10,477
| +30% | +$216K |
|
1584
Trimble
TRMB
$19.2B
| $914K | ﹤0.01% |
16,337
+1,376
| +9% | +$76.9K |
|
1585
Pennant Group
PNTG
$840M
| $901K | ﹤0.01% |
+38,866
| New | +$901K |
|
1586
Ardelyx
ARDX
$1.57B
| $901K | ﹤0.01% |
121,599
+16,943
| +16% | +$126K |
|
1587
Mine Safety
MSA
$6.67B
| $896K | ﹤0.01% |
+4,775
| New | +$896K |
|
1588
Ultrapar
UGP
$4.17B
| $896K | ﹤0.01% |
229,175
-1,989
| -0.9% | -$7.78K |
|
1589
ALX Oncology
ALXO
$65.3M
| $879K | ﹤0.01% |
145,717
+18,680
| +15% | +$113K |
|
1590
BorgWarner
BWA
$9.53B
| $878K | ﹤0.01% |
27,235
-7,874
| -22% | -$254K |
|
1591
Verrica Pharmaceuticals
VRCA
$48.3M
| $874K | ﹤0.01% |
11,992
+1,753
| +17% | +$128K |
|
1592
Oric Pharmaceuticals
ORIC
$1.06B
| $868K | ﹤0.01% |
122,823
+10,850
| +10% | +$76.7K |
|
1593
Kyndryl
KD
$7.57B
| $867K | ﹤0.01% |
32,958
+20,688
| +169% | +$544K |
|
1594
Design Therapeutics
DSGN
$367M
| $860K | ﹤0.01% |
256,627
+42,317
| +20% | +$142K |
|
1595
Strategy Inc Common Stock Class A
MSTR
$95.2B
| $858K | ﹤0.01% |
6,230
-200,920
| -97% | -$27.7M |
|
1596
Caribou Biosciences
CRBU
$174M
| $858K | ﹤0.01% |
523,250
+81,444
| +18% | +$134K |
|
|
ANSS
1597
DELISTED
Ansys
ANSS
| $852K | ﹤0.01% |
2,649
+169
| +7% | +$54.3K |
|
1598
Black Diamond Therapeutics
BDTX
$167M
| $847K | ﹤0.01% |
181,675
+15,989
| +10% | +$74.5K |
|
1599
Atea Pharmaceuticals
AVIR
$267M
| $845K | ﹤0.01% |
255,166
-94,838
| -27% | -$314K |
|
1600
Western Union
WU
$2.86B
| $832K | ﹤0.01% |
68,091
-28,885
| -30% | -$353K |
|